OncoSec Medical (NASDAQ:ONCS) Now Covered by StockNews.com

StockNews.com started coverage on shares of OncoSec Medical (NASDAQ:ONCSGet Rating) in a report issued on Tuesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Several other research firms also recently weighed in on ONCS. Zacks Investment Research downgraded OncoSec Medical from a “hold” rating to a “sell” rating in a research report on Tuesday, April 12th. BTIG Research cut their target price on OncoSec Medical from $10.00 to $5.00 and set a “buy” rating on the stock in a research report on Wednesday, March 16th.

NASDAQ:ONCS opened at $1.04 on Tuesday. OncoSec Medical has a 1 year low of $0.75 and a 1 year high of $5.34. The stock’s 50 day simple moving average is $1.03 and its two-hundred day simple moving average is $1.23. The company has a market cap of $40.92 million, a price-to-earnings ratio of -1.00 and a beta of 1.99.

OncoSec Medical (NASDAQ:ONCSGet Rating) last released its earnings results on Tuesday, March 15th. The biotechnology company reported ($0.25) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.14). On average, equities research analysts expect that OncoSec Medical will post -0.59 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Two Sigma Advisers LP boosted its holdings in OncoSec Medical by 128.2% during the 3rd quarter. Two Sigma Advisers LP now owns 361,401 shares of the biotechnology company’s stock valued at $770,000 after acquiring an additional 203,010 shares during the period. Salzhauer Michael boosted its holdings in OncoSec Medical by 15.9% during the 4th quarter. Salzhauer Michael now owns 321,354 shares of the biotechnology company’s stock valued at $308,000 after acquiring an additional 44,042 shares during the period. Geode Capital Management LLC boosted its holdings in OncoSec Medical by 7.1% during the 4th quarter. Geode Capital Management LLC now owns 262,478 shares of the biotechnology company’s stock valued at $251,000 after acquiring an additional 17,467 shares during the period. Renaissance Technologies LLC boosted its holdings in OncoSec Medical by 140.0% during the 4th quarter. Renaissance Technologies LLC now owns 249,361 shares of the biotechnology company’s stock valued at $239,000 after acquiring an additional 145,463 shares during the period. Finally, Long Focus Capital Management LLC purchased a new position in OncoSec Medical during the 4th quarter valued at $66,000. Institutional investors own 16.39% of the company’s stock.

About OncoSec Medical (Get Rating)

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor.

Recommended Stories

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.